Log in

AtriCure Stock Price, News & Analysis (NASDAQ:ATRC)

$27.26
-0.05 (-0.18 %)
(As of 10/18/2019 04:00 PM ET)
Today's Range
$27.12
Now: $27.26
$27.64
50-Day Range
$23.75
MA: $25.50
$27.50
52-Week Range
$22.57
Now: $27.26
$34.39
Volume143,245 shs
Average Volume228,638 shs
Market Capitalization$1.06 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.3
AtriCure, Inc develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems to medical centers in the United States and internationally. The company offers Isolator Synergy and Isolator Synergy Access clamps for the treatment of persistent and long-standing persistent atrial fibrillation concomitant to other open-heart surgical procedures; EPi-Sense guided coagulation system used for the coagulation of tissue; and COBRA Fusion surgical ablation system to combine bipolar temperature-controlled radio frequency energy control with monopolar energy. Read More…

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
Current SymbolNASDAQ:ATRC
CUSIP04963C20
Phone513-755-4100

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$201.63 million
Book Value$6.47 per share

Profitability

Net Income$-21,140,000.00

Miscellaneous

Employees620
Market Cap$1.06 billion
Next Earnings Date10/30/2019 (Confirmed)
OptionableOptionable

Receive ATRC News and Ratings via Email

Sign-up to receive the latest news and ratings for ATRC and its competitors with MarketBeat's FREE daily newsletter.


AtriCure (NASDAQ:ATRC) Frequently Asked Questions

What is AtriCure's stock symbol?

AtriCure trades on the NASDAQ under the ticker symbol "ATRC."

How were AtriCure's earnings last quarter?

AtriCure Inc. (NASDAQ:ATRC) released its quarterly earnings data on Tuesday, July, 30th. The medical device company reported ($0.17) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.18) by $0.01. The medical device company earned $58.90 million during the quarter, compared to analysts' expectations of $57.76 million. AtriCure had a negative return on equity of 13.06% and a negative net margin of 9.46%. The business's revenue for the quarter was up 13.7% on a year-over-year basis. During the same quarter last year, the firm earned ($0.19) earnings per share. View AtriCure's Earnings History.

When is AtriCure's next earnings date?

AtriCure is scheduled to release their next quarterly earnings announcement on Wednesday, October 30th 2019. View Earnings Estimates for AtriCure.

How can I listen to AtriCure's earnings call?

AtriCure will be holding an earnings conference call on Wednesday, October 30th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

What guidance has AtriCure issued on next quarter's earnings?

AtriCure updated its FY 2019 earnings guidance on Monday, August, 12th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $224.5-228.5 million, compared to the consensus revenue estimate of $227.06 million.

What price target have analysts set for ATRC?

5 equities research analysts have issued twelve-month price objectives for AtriCure's shares. Their forecasts range from $30.00 to $40.00. On average, they anticipate AtriCure's share price to reach $36.20 in the next twelve months. This suggests a possible upside of 32.8% from the stock's current price. View Analyst Price Targets for AtriCure.

What is the consensus analysts' recommendation for AtriCure?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AtriCure in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for AtriCure.

Has AtriCure been receiving favorable news coverage?

News headlines about ATRC stock have trended somewhat negative recently, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. AtriCure earned a daily sentiment score of -1.5 on InfoTrie's scale. They also assigned news coverage about the medical device company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for AtriCure.

Are investors shorting AtriCure?

AtriCure saw a drop in short interest during the month of September. As of September 30th, there was short interest totalling 1,180,000 shares, a drop of 6.3% from the August 30th total of 1,260,000 shares. Based on an average daily volume of 260,700 shares, the days-to-cover ratio is currently 4.5 days. Currently, 3.1% of the shares of the stock are short sold. View AtriCure's Current Options Chain.

Who are some of AtriCure's key competitors?

What other stocks do shareholders of AtriCure own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AtriCure investors own include Amgen (AMGN), Gilead Sciences (GILD), Neurocrine Biosciences (NBIX), AbbVie (ABBV), Micron Technology (MU), bluebird bio (BLUE), Cellectis (CLLS), Exelixis (EXEL), Galectin Therapeutics (GALT) and Heron Therapeutics (HRTX).

Who are AtriCure's key executives?

AtriCure's management team includes the folowing people:
  • Mr. Michael H. Carrel, CEO, Pres & Director (Age 48)
  • Mr. M. Andrew Wade CPA, Sr. VP & CFO (Age 44)
  • Mr. Douglas J. Seith, Chief Operating Officer (Age 53)
  • Mr. Salvatore Privitera, Chief Technology Officer (Age 52)
  • Mr. Justin J. Noznesky, Sr. VP of Marketing & Bus. Devel. (Age 41)

Who are AtriCure's major shareholders?

AtriCure's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Peregrine Capital Management LLC (2.08%). Company insiders that own AtriCure stock include B Kristine Johnson, Douglas J Seith, Elizabeth D Krell, Justin J Noznesky, M Andrew Wade, Mark A Collar, Michael H Carrel and Regina E Groves. View Institutional Ownership Trends for AtriCure.

Which institutional investors are buying AtriCure stock?

ATRC stock was acquired by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC. Company insiders that have bought AtriCure stock in the last two years include B Kristine Johnson and Regina E Groves. View Insider Buying and Selling for AtriCure.

How do I buy shares of AtriCure?

Shares of ATRC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is AtriCure's stock price today?

One share of ATRC stock can currently be purchased for approximately $27.26.

How big of a company is AtriCure?

AtriCure has a market capitalization of $1.06 billion and generates $201.63 million in revenue each year. The medical device company earns $-21,140,000.00 in net income (profit) each year or ($0.94) on an earnings per share basis. AtriCure employs 620 workers across the globe.View Additional Information About AtriCure.

What is AtriCure's official website?

The official website for AtriCure is http://www.atricure.com/.

How can I contact AtriCure?

AtriCure's mailing address is 7555 INNOVATION WAY, MASON OH, 45040. The medical device company can be reached via phone at 513-755-4100.


MarketBeat Community Rating for AtriCure (NASDAQ ATRC)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  414 (Vote Outperform)
Underperform Votes:  296 (Vote Underperform)
Total Votes:  710
MarketBeat's community ratings are surveys of what our community members think about AtriCure and other stocks. Vote "Outperform" if you believe ATRC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ATRC will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/19/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel